Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • On the Market
  • Published:

Imaging of amyloid-β deposits in brains of living mice permits direct observation of clearance of plaques with immunotherapy

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Imaging of amyloid-β deposits in the live mouse.
Figure 2: Clearance of dense-core amyloid-β deposits after immunotherapy.
Figure 3: In vivo imaging of amyloid-β deposits in 20-month-old homozygous PDAPP mice.
Figure 4: Histological analysis of imaged brains from 20-month-old homozygous PDAPP mice using biotinylated antibody 3D6 shows an extraordinarily high level of amyloid-β deposits throughout the cortex and hippocampal formation.
Figure 5: Marked local microglial activation, as assessed with biotin-labeled tomato lectin, occurs 3 days after the skull preparation and imaging.
Figure 6: Confocal thin optical sections (0.2 μm) were reconstructed to illustrate the intimate relationship of microglia with remaining amyloid-β three days after treatment with 10D5-fluorescein.

References

  1. Braak, H. & Braak, E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 82, 239–259 (1991).

    Article  CAS  Google Scholar 

  2. Gomez-Isla, T. et al. Profound loss of layer II entorhinal cortex neurons occurs in very mild Alzheimer's disease. J. Neurosci. 16, 4491–4500 (1996).

    Article  CAS  Google Scholar 

  3. Davis, D.G., Schmitt, F.A., Wekstein, D.R. & Markesbery, W.R. Alzheimer neuropathologic alterations in aged cognitively normal subjects. J. Neuropathol. Exp. Neurol. 58, 376–388 (1999).

    Article  CAS  Google Scholar 

  4. Naslund, J. et al. Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline. JAMA 283, 1571–1577 (2000).

    Article  CAS  Google Scholar 

  5. Games, D. et al. Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein. Nature 373, 523–527 (1995).

    Article  CAS  Google Scholar 

  6. Irizarry, M.C. et al. Abeta deposition is associated with neuropil changes, but not with overt neuronal loss in the human amyloid precursor protein V717F (PDAPP) transgenic mouse. J. Neurosci. 17, 7053–7059 (1997).

    Article  CAS  Google Scholar 

  7. Schenk, D. et al. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 400, 173–177 (1999).

    Article  CAS  Google Scholar 

  8. Denk, W., Strickler, J.H. & Webb, W.W. Two-photon laser scanning fluorescence microscopy. Science 248, 73–76 (1990).

    Article  CAS  Google Scholar 

  9. Svoboda, K., Denk, W., Kleinfeld, D. & Tank, D.W. In vivo dendritic calcium dynamics in neocortical pyramidal neurons. Nature 385, 161–165 (1997).

    Article  CAS  Google Scholar 

  10. Yang, X. et al. Dynamic mapping at the laminar level of odor-elicited responses in rat olfactory bulb by functional MRI. Proc. Natl. Acad. Sci. USA 95, 7715–7720 (1998).

    Article  CAS  Google Scholar 

  11. Hyman, B.T., Tanzi, R.E., Marzloff, K., Barbour, R. & Schenk, D. Kunitz protease inhibitor-containing amyloid beta protein precursor immunoreactivity in Alzheimer's disease. J. Neuropathol. Exp. Neurol. 51, 76–83 (1992).

    Article  CAS  Google Scholar 

  12. Vigo-Pelfry, C. et al. Elevation of microtubule-associated protein tau in the cerebrospinal fluid of patients with Alzheimer's disease. Neurology 45, 788–793 (1995).

    Article  Google Scholar 

  13. Bard, F. et al. Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nature Med. 6, 916–919 (2000).

    Article  CAS  Google Scholar 

  14. Solomon, B. et al. Monoclonal antibodies inhibit in vitro fibrillar aggregation of the Alzheimer beta-amyloid peptide. Proc. Natl. Acad. Sci. USA 93, 452–455 (1996).

    Article  CAS  Google Scholar 

Download references

Acknowledgements

This work was supported by grants from the National Institute on Aging (AG08487, P01AG15453 and T32GM07753), and support from the Alzheimer Association and the Walters Family Foundation. An unrestricted gift from Elan Pharmaceuticals supported housing costs for the animals.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Bradley T. Hyman.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bacskai, B., Kajdasz, S., Christie, R. et al. Imaging of amyloid-β deposits in brains of living mice permits direct observation of clearance of plaques with immunotherapy. Nat Med 7, 369–372 (2001). https://doi.org/10.1038/85525

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/85525

This article is cited by

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing